Clinical Trials Logo

Coronary Disease clinical trials

View clinical trials related to Coronary Disease.

Filter by:

NCT ID: NCT03473860 Not yet recruiting - Clinical trials for Coronary Artery Disease

the Change of CEM and the Prognosis of Coronary Artery Disease in Real Clinical Practice

CCEMPCAD
Start date: April 1, 2018
Phase:
Study type: Observational

The purpose of this study is to investigate the change of total cholesterol content of erythrocyte membranes (CEM) in patients with coronary artery disease treated with secondary prevention drugs, and the correlation with the prognosis.

NCT ID: NCT03454724 Not yet recruiting - Clinical trials for Coronary Artery Disease

Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.

MeReS100-China
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

This is a Multi Center Randomized Control Study of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System in treatment of approximately 484 subjects with Coronary Artery Disease in China. Eligible subjects shall have up to two de novo lesions in different epicardial vessels (One lesion in each coronary artery or it's major branch),Target lesion shall have visually estimated diameter stenosis ≥ 70% (or ≥ 50% and has clinical evidence of myocardial ischemia), lesion length ≤ 24mm, reference vascular diameter visually ≥ 2.75mm and ≤ 4.0mm. And subjects must meet all the study inclusion / exclusion criteria before enrolment in the study.All subjects shall accept clinical follow up at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years post procedure.

NCT ID: NCT03445273 Not yet recruiting - Coronary Disease Clinical Trials

Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery

MONET
Start date: November 21, 2018
Phase:
Study type: Observational [Patient Registry]

The MONET registry will include any patient with previous coronary stenting undergoing any type of surgery or operative endoscopic/endovascular procedure. The effects of the application of the Consensus Document "Stent and Surgery-2" on perioperative antiplatelet therapy will be assessed. The study will also assess ischemic and hemorrhagic events in relation to the application of the Consensus Document and length of any antiplatelet discontinuation and delay in performing surgical procedures.

NCT ID: NCT03423511 Not yet recruiting - Clinical trials for Coronary Artery Disease

Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.

CRYSTAL
Start date: December 31, 2021
Phase: N/A
Study type: Interventional

To compare MiStent to either the Xience or Promus stents.with the primary objective being to assess the safety and efficacy of the MiStent in a patient population requiring revascularization of de novo obstructive lesions of coronary arteries in patients with stable and unstable coronary artery disease (CAD) including non ST-Elevation Myocardial Infarction (NSTEMI)

NCT ID: NCT03405506 Not yet recruiting - Clinical trials for Coronary Artery Disease

Functional Diagnostic Accuracy of Quantitative Flow Ratio in Tandem Lesions and Virtual Stenting

FORTRESS
Start date: February 2, 2018
Phase: N/A
Study type: Observational [Patient Registry]

Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. Virtual stent implantation technique combined with QFR was recently developed to predict the functional significance of coronary stenosis as if the stenosis was revascularized. The purpose of this study is to evaluate the diagnostic accuracy of QFR in in tandem lesions with fractional flow reserve (FFR) as the reference standard. The secondary purpose is to evaluate the diagnostic accuracy of QFR-based virtual stent technique in predicting the FFR values after revascularizing the culprit lesion.

NCT ID: NCT03398577 Not yet recruiting - Clinical trials for Coronary Disease With Diabetes Mellitus

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Start date: February 1, 2018
Phase: Phase 4
Study type: Interventional

The aim of this study is to explore the effect of newly added SGLT2I medication or placebo, to standard medication regimen in diabetic patients with documented stable coronary disease. Therefore, in the present study the investigators plan to focus on possible anti-inflammatory and athero-thrombotic protective effects of Dapagliflozin compared to placebo, in secondary prevention population of stable coronary patients with diabetes. Additionally, the investigators will explore NT proBNP dynamics, which related to ventricular filling pressures in this specific population.

NCT ID: NCT03398096 Not yet recruiting - Clinical trials for Coronary Artery Disease

Improvement of Cardiac Function in Patients With Ischemic Cardiomyopathy by Extracorporeal Shock Wave Therapy: a Multicenter Clinical Study

Start date: March 30, 2018
Phase: N/A
Study type: Interventional

Cardiac shock wave therapy (CSWT) is a noninvasive new therapeutic option in the treatment of chronic refractory angina pectoris. Many domestic and international researches have revealed that CSWT contributes to revascularization by stimulating angiogenesis. We were aimed to evaluate the safety and efficiency of CSWT in the treatment of refractory angina.

NCT ID: NCT03389529 Not yet recruiting - Stroke Clinical Trials

the Change of Cholesterol Efflux Capacity and Coronary Artery Disease in Real Clinical Practice

Start date: April 1, 2018
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the change of cholesterol efflux capacity in patients with coronary artery disease treated with secondary prevention drugs, and the correlation with the prognosis.

NCT ID: NCT03375528 Not yet recruiting - Clinical trials for Coronary Artery Disease

Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

If intimal growth is such that the initial lumen is narrowed significantly, distal blood flow is restricted and chronic tissue ischemia results. This occurs in native coronary arteries and during restenosis after coronary angioplasty or failure of some coronary vein grafts. Stent implantation has become the principal revascularization technique for coronary artery disease. But, in-stent restenosis (ISR) by neointimal hyperplasia persists as a significant limitation of this procedure in the era of drug eluting stent (DES). Coronary intervention might induce an inflammatory response by arterial wall damage, release of inflammatory and chemoattractant factors resulting in leukocyte and platelet activation. Then, Migration and proliferation of neointimal smooth muscle cells together with the deposition of extracellular matrix might lead to the development of ISR. It is known that matrix metalloproteinases (MMPs) play a key role in the pathogenesis of restenosis by controlling extracellular matrix degradation and the release of matrix-degrading MMPs, including MMP -2 and MMP-9, which facilitate intimal remodeling after angioplasty. Previous studies showed that increased levels of MMPs in coronary arteries undergoing percutaneous intervention may be associated with vascular remodeling and restenosis by promoting migration of vascular smooth muscle cells. Recently, Gregory et al. demonstrated that elevated serum activities of MMP-2 and -9 are associated with dramatically increased restenosis rates after PCI with implantation of DES. In patients with DESs, determination of MMP levels might be useful for identification of patients who are at high risk for ISR. However, not much is known about the relationship between MMPs and neointimal hyperplasia in patients with DES. In this study, the serum activity of MMP-2 and 9 were investigated in patients who had undergone follow-up coronary angiography with intravascular ultrasound (IVUS), which performed at 9 months post-DES implantation. Our aim was to evaluate if individual or combined levels of MMPs were associated with increased neointimal hyperplasia volume, that is, to evaluate the relationship, correlation between the levels of MMPs and neointimal hyperplasia volume.

NCT ID: NCT03277079 Not yet recruiting - Clinical trials for Coronary Artery Disease

Low Dose Statins, Ezetimibe and Nutraceuticals

TACO
Start date: October 1, 2017
Phase: Phase 4
Study type: Interventional

It remains unknown if the association between moderate to low intensity statin therapy and ezetimibe and nutraceuticals might have a therapeutic role in high-intensity statin intolerant patients